Search

The purpose of this work was to study the associations of RS3846663 variants in the HMG-CoA reductase gene with effectiveness of statin therapy. For the coronary heart disease patients group, 127 subjects (59 females and 68 males) were selected. In order to identify single nucleotide polymorphism, minisequencing was applied with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-ToF/MS) for subsequent detection of the reaction products. In this study, the statin significantly reduced total cholesterol, low density lipoprotein and triglyceride levels, both after one month and two months of treatment. It was established that carrying CC and TT genotypes of RS3846663 in HMG-CoA reductase gene had no impact on the change in total cholesterol and almost all values in the spectrum of lipoproteins during statin therapy, regardless of its duration. A weak tendency to an increase in high-density lipoproteins was observed in heterozygous CT carriers after one month of statin treatment. In addition, no significant association was found between carrying heterozygous CT genotype and TT homozygote and achievement of target levels of lipoproteins and total cholesterol during simvastatin treatment, regardless of its duration.

The purpose of this study was to establish an association between polymorphism rs3846663 in the HMG-CoA reductase gene and total cholesterol in relatively healthy individuals, without gender specification, as well as in men and in women separately. The study was conducted in a group of 173 relatively healthy individuals (105 women, 68 men). In order to identify single nucleotide polymorphism, minisequencing was applied with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-ToF/MS) for subsequent detection of the reaction products. In this study, total cholesterol levels in carriers of pathological genotypes (CT and TT) of rs3846663 in the HMG-CoA reductase gene were significantly higher than in individuals with a normal CC genotype. It was also found that carrying CT and TT genotypes increases the risk of elevated total cholesterol as compared to the target levels. Total cholesterol in women carrying CT and TT genotypes of rs3846663 in the HMG-CoA reductase gene was statistically significantly higher. Moreover, the risk of elevated total cholesterol was also high. In healthy men, the presence of a pathological T allele did not affect the total cholesterol levels.